TD Cowen assumed coverage of Johnson & Johnson with a Buy rating and $250 price target The firm sees the company’s “strong” product portfolio driving 7% annual sales growth through 2032. Johnson & Johnson’s pipeline provides visibility on long-term growth, and its margin expansion creates above-peer earnings power through 2032, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- Johnson & Johnson: Diversified Growth, Robust Pipeline, and Attractive Risk‑Reward Support Buy Rating
- Johnson & Johnson product cycle momentum continuing, says Goldman Sachs
- Johnson & Johnson announces launch of Varipulse Pro in Europe
- Johnson & Johnson price target raised to $285 from $274 at Citi
- Trump Trade: U.S. strengthens tariffs on steel, aluminum, copper imports